Title: Protection afforded by post-infection SARS-CoV-2 vaccine doses: a cohort

2 study in Shanghai

1

3

6

7

18

19

28

29

30

31

- Bo Zheng^{1†}, Bronner Gonçalves^{2†}, Pengfei Deng^{3†}, Weibing Wang^{1,4}, Jie Tian¹, 4
- Xueyao Liang¹, Ye Yao⁵*, Caoyi Xue³* 5
- 8 1 Department of Epidemiology, School of Public Health, Fudan University, Shanghai
- 9 200032, China
- 2 Department of Comparative Biomedical Sciences, School of Veterinary Medicine, 10
- 11 University of Surrey, Guildford, UK
- 3 Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, 12
- 13 200120, China
- 4 Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, 14
- Shanghai 200032, China 15
- 5 School of Public Health, Shanghai Institute of Infectious Disease and Biosecurity, 16
- 17 Fudan University, Shanghai 200032, China
- 20 † These authors contributed equally to this work.
- * Corresponding authors: 21
- 22 Dr. Ye Yao
- 23 School of Public Health, Fudan University, 138 Yi Xue Yuan Road, Shanghai 200032,
- China (e-mail: yyao@fudan.edu.cn). 24
- 25 Dr. Caoyi Xue
- Shanghai Pudong New Area Center for Disease Control and Prevention, 3039 26
- 27 Zhangyang Road, Shanghai, 200120, China (e-mail: xuecaoyi83@163.com)

³³ NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65 66 **ABSTRACT** Background: In many settings, a large fraction of the population has both been vaccinated against and infected by SARS-CoV-2. Hence, quantifying the protection provided by post-infection vaccination has become critical for policy. We aimed to estimate the protective effect against SARS-CoV-2 reinfection of an additional vaccine dose after an initial Omicron variant infection. **Methods:** We report a retrospective, population-based cohort study performed in Shanghai, China, using electronic databases with information on SARS-CoV-2 infections and vaccination history. We compared reinfection incidence by postinfection vaccination status in individuals initially infected during the April-May 2022 Omicron variant surge in Shanghai and who had been vaccinated before that period. Cox models were fit to estimate adjusted hazard ratios (aHR). Results: 275,896 individuals were diagnosed with RT-PCR-confirmed SARS-CoV-2 infection in April-May 2022; 199,312/275,896 were included in analyses on the effect of a post-infection vaccine dose. Post-infection vaccination provided protection against reinfection (aHR 0.82; 95% CI 0.79-0.85). For patients who had received one, two or three vaccine doses before their first infection, hazard ratios for the postinfection vaccination effect were 0.84 (0.76-0.93), 0.87 (0.83-0.90) and 0.96 (0.74-1.23), respectively. Vaccination within 30 and 90 days before the second Omicron wave provided different degrees of protection (in aHR): 0.51 (0.44-0.58), and 0.67 (0.61-0.74), respectively. Moreover, for all vaccine types, but to different extents, a post-infection dose given to individuals who were fully vaccinated before first infection was protective. Conclusions: In previously vaccinated and infected individuals, an additional vaccine dose provided protection against Omicron variant reinfection. These observations will inform future policy decisions on COVID-19 vaccination in China and other countries. **Keywords**: COVID-19, vaccine effectiveness, hybrid immunity, reinfection, Omicron variant.

1 Introduction

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

Four years after the first reports of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the Coronavirus disease (COVID-19) pandemic continues to be a global concern, especially due to the risk of emergence of new variants[1, 2]. In most countries, the variant that is currently epidemiologically dominant is the Omicron[3, 4], which, due to its increased transmissibility and high number of mutations, led to significant increases in the number of infections in 2022[5]. Omicron variant infections were first observed in China in December 2021[3], and in Shanghai, the spread of the Omicron BA.2 sublineage led to a substantial increase in COVID-19 incidence between February 26 and June 30, 2022[6].

In December 2022[7], an important change in the COVID-19 policy in China, namely the end of most social distancing measures and of mass screening activities, was associated with a second surge in SARS-CoV-2 infections in Shanghai. The current circulation of the virus in the Shanghainese population and reports of vaccine fatigue mean that it is important to estimate the protective effect of vaccination against reinfection in this population. In this study, we aimed to quantify the effect of vaccine doses given after a first infection on the risk of subsequent infection. For that, we used data collected during the first Omicron variant wave, when hundreds of thousands of individuals tested real-time polymerase chain reaction (RT-PCR)positive for SARS-CoV-2 infection[8] in Shanghai, of which 275,896 individuals in Pudong. The fact that the population in Shanghai was mostly SARS-CoV-2 infection naïve before the spread of the Omicron variant provides a unique opportunity to estimate the real-world benefit of post-infection vaccine doses in a population that was first exposed to infection during a relatively short and well-defined time window. We further investigated whether the number of pre-infection vaccination doses modified the protective effect of the post-infection dose against Omicron BA.5 sublineage.

2 **Results**

2.1 Demographic characteristics of the study population

Of the 275,896 individuals with RT-PCR-confirmed SARS-CoV-2 infection during the first Omicron variant wave (from April 1 to May 31, 2022) in Pudong, Shanghai, 1,227 individuals died from reasons unrelated to COVID-19 between the

first infection and November 2022 and were excluded from our analysis. Most first infections (243,906, 88.8%) occurred in April; for 306 (0.1%) individuals, information on the date of first infection was not available. In April 2022, more than half of the study population (68.6%) had completed full vaccination and one third (34.4%) had received booster vaccination.

To assess the effect of an additional vaccine dose given after infection, the analytic sample consisted of 199,312 individuals (Figure 1). 85,804 were women (43.1%); 836 (0.4%) had gender information missing. 38.1% of the study participants were aged 20 to 39 years and only 0.9% were aged 0 to 6 years.

2.2 Vaccination after first Omicron variant infection

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

Figure 2 (Panel A) shows vaccination coverage in the analytic population over time. In April 2022, a series of emergency epidemic prevention measures, including mass screening with Nucleic Acid Amplification Tests (NAATs), city-wide lockdown, home quarantine of residents, were implemented in Shanghai, leading to the temporary suspension of vaccination in April and May 2022. By the end of the study period, January 2023, 69.5% (Table S1) of the study participants had completed full vaccination, and 38.4% booster vaccination (Figure S1). Vaccination coverages for the first, second, third, and fourth vaccine doses were 72.7%, 67.6%, 37.4% and 0.3%, respectively.

As mentioned above, only participants who had received vaccination before the first infection were included in this analysis. After infection, 10,241 (5.1%), 5,096 (2.6%), and 810 (0.4%) individuals received another vaccine dose in August, and during the periods from September to November 2022 and from December 2022 to January 2023, respectively. Between their first infection, in April-May 2022, and January 2023, 17.4% (2,466/14,131) of the study participants who had one preinfection dose received a second dose of COVID-19 vaccine, and 13.8% (12,886/93,087) of those who had received two pre-infection doses received a third vaccine dose. Only 1.0% (142/14,131) of the study participants who had one preinfection dose received two doses of COVID-19 vaccine after infection, and 0.2% (144/93,087) of those who had received two pre-infection doses received two vaccine doses after infection (Table S5). All individuals with three pre-infection vaccine doses who received a fourth dose (795/92,094, 0.9%) received the post-infection dose in December 2022; for 793 of these participants, the vaccine dose received in

December was their second booster vaccination (for the other 2, their fourth dose was 133

the first booster vaccination; see Supplementary Appendix for more information about

vaccine policy in Shanghai).

134

135

136 137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

2.3 SARS-CoV-2 reinfections

Among the study participants, 48,651/199,312 (24.4%) had SARS-CoV-2 reinfection. The median age of individuals with no evidence of reinfection was 41.7 years (IOR: 31.0, 55.7 years), and of individuals with confirmed SARS-CoV-2 reinfection, 45.8 years (IQR: 34.0, 55.9 years) (Table S1). The median time interval between the first infection and reinfection was 244.7 days (IQR: 237.4, 250.0), which implies that the risk of misclassifying a long infection as a reinfection was low.

Figure 2 (Panels B and C) shows the cumulative incidence of SARS-CoV-2 reinfection by vaccination status. Overall, individuals who were not vaccinated after their first infection were more often reinfected compared to those vaccinated after infection. The percentage of female individuals who became reinfected was lower than that of male individuals (22.4% vs. 26.1%; **Table 1**); and reinfection was more common in participants aged 40 to 59 years compared to those aged 20 to 39 (29.4% vs. 22.4%). Individuals originally from other provinces had a slightly higher risk of reinfection compared to individuals from Shanghai (20.9% vs. 18.9%). The risks for retired individuals, for those of working age who were not working, and for those working were 22.5, 21.0, and 20.8%, respectively.

2.4 Vaccine effectiveness

For individuals who had received at least one vaccine dose before infection during the first Omicron variant wave, post-infection vaccination was protective against reinfection (adjusted hazard ratio [aHR] 0.82, 95% CI 0.79, 0.85). As shown in Figure 3, this protective effect was observed in subgroups defined by the number of pre-infection vaccine doses: aHR of 0.84 (95% CI, 0.76, 0.93) and 0.87 (95% CI, 0.83, 0.90) for one and two pre-infection doses respectively; and for patients with three vaccine doses prior to infection, the association was not statistically significant (aHR: 0.96 [0.74, 1.23]). When analyses are stratified by partial and full vaccination status before the first infection, an additional vaccine dose was protective (aHR 0.76 [0.68, 0.84], and 0.93 [0.89, 0.97], respectively); and among individuals who had received booster vaccination before the spread of the first Omicron variant wave in Shanghai, the hazard ratio estimate was consistent with a more limited effect (aHR:

0.95 [0.75, 1.22]).

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189 190

191

192

193

194

195

196

197

198

In analyses stratified by demographic characteristics (Figure 4), post-infection vaccine doses were protective in both female (aHR 0.81 [0.76, 0.86]) and male individuals (aHR 0.83 [0.79, 0.87]). Vaccine dose after the first Omicron variant wave was more protective for participants aged 60 years or older (aHR 0.73 [0.69, 0.78] compared to other age groups. The estimated aHR for individuals who were asymptomatic during their first infection was 0.80 (0.74, 0.87), and for those who were symptomatic during the first infection was 1.01 (0.78, 1.29).

As a secondary analysis, we estimated vaccine effects by calendar time of vaccination. Additional vaccine doses given within 30 and 90 days of the second Omicron variant wave were associated with lower hazard of reinfection (aHRs 0.51 [0.44, 0.58], 0.67 [0.61, 0.74], respectively). Note that in this secondary analysis, exposed and unexposed individuals were matched using propensity scores. We also performed a secondary analysis by vaccine type: for example, we compared patients who completed full vaccination before first infection and received a post-infection Ad5-nCOV vaccine dose, with those who completed full vaccination before first infection and received no vaccination post-infection; this approach was repeated for inactivated vaccines and recombinant protein vaccines (Table S6). Note that in this analysis, the types of vaccines administered before infection often align between the post-infection vaccination group and the post-infection non-vaccination group (see Table S6). Post-infection Ad5-nCoV vaccine dose given to those had received full vaccination before the first infection was associated with lower hazard of reinfection (0.67, 95% CI: 0.56, 0.80); a protective effect was also observed for other vaccine types: inactivated vaccines (0.92, 95% CI: 0.87, 0.98) or recombinant protein vaccines (0.77, 95% CI: 0.64, 0.92). We performed an additional ad-hoc sensitivity analysis using a Cox model that was not adjusted for the severity of the first infection. As shown in Figure S2, our findings were not affected by the non-inclusion of disease severity in the survival analysis model.

3 **Discussion**

We aimed to estimate the added value of a vaccine dose given after SARS-CoV-2 infection in individuals who had received COVID-19 vaccination before the emergence of the Omicron variant. Although quantification of the protective effect of additional vaccine doses in individuals who have been both exposed to infection and

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

previously vaccinated is a public health policy priority, as in many settings this group represents a large fraction of the population, studies on this question are often complicated by the variable timing of infection, vaccination and reinfection. Here, we leveraged the epidemiological history of COVID-19 in Shanghai municipality, where exposure to first and second SARS-CoV-2 infections occurred during well-defined periods of time, and large electronic databases allowed analyses of vaccination and infection history. Our study showed that vaccine doses given after the first Omicron variant infection reduced the risk of reinfection with this variant during a second, large surge of infections in the city. We also assessed the impact of the timing of vaccination relative to the second Omicron variant wave, and presented secondary and sensitivity analyses. This study will be used to guide COVID-19 vaccination policy in the municipality of Shanghai, and have implications for the rest of the country.

In Shanghai, COVID-19 vaccination started in February 2021 for individuals aged between 18 and 59 years, and over the following months, both older residents and children were included in the vaccination programme[9]. By the time of the first surge of Omicron variant infections, less than 70% of Shanghai residents aged 60 to 79 years had completed a primary vaccination series, and 40% had received a booster dose[8]. This was the context in which the population in this municipality was exposed to a first large epidemic of SARS-CoV-2 infections. The change in policy in December 2022 that was associated with a significant increase in the number of infections was our primary motivation to study the additional protection afforded by vaccine doses after infection. Indeed, although epidemiological studies have been reported on the effect of vaccination against reinfection, primarily in Europe[10], North America[11] and Middle East[12], there is limited evidence from settings similar to that in Shanghai, where both the infection and vaccination histories, in terms of vaccine types, differ considerably from those in most Western countries. As individuals increasingly question the benefit of getting vaccinated after COVID-19 recovery, evidence generated locally is necessary.

Previous studies have shown that infection alone can result in immune responses that protect against Omicron variant reinfection. For example, a study in Qatar, with a test-negative design, found that an earlier Omicron variant infection provided protection against symptomatic BA.4 or BA.5 reinfection[13]. There are also different types of evidence that support vaccination post-infection. In Israel, post-infection

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

variant infection.

vaccination protected against reinfection in individuals with no history of preinfection vaccine doses[14], and prior SARS-CoV-2 infection was associated with lower risk for breakthrough infection among individuals receiving the BNT162b2 or mRNA-1273 vaccines in Qatar[15]. Further, a recent cohort study, performed in the US, of previously infected individuals who were unvaccinated at the time of first infection suggest that vaccination after recovery from COVID-19 decreased risk of reinfection by approximately half[16], which was consistent with a case-control study also conducted in the US[17]. Although our research question was different from those in these studies, data from Shanghai suggest that a vaccine dose after infection in individuals who had received at least one dose of SARS-CoV-2 vaccine before infection provides protection against reinfection. We note that whilst an additional vaccine dose was protective for individuals who had received one or two vaccine doses before the first Omicron variant wave, for those individuals who had received three vaccine doses, the evidence for a protective effect was limited. A possible explanation relates to the timing of the additional vaccine dose: for all individuals with three pre-infection vaccine doses, the post-infection dose was given in December 2022 and, as a few weeks are required for immunologic boosting, the relatively short follow-up might have been insufficient to detect an effect. Similarly, evidence that an additional vaccine dose was protective for individuals who had received booster vaccination before the spread of the first Omicron variant wave in Shanghai was

In a secondary analysis that assessed the impact of the timing of the additional vaccine dose on the estimated effect, we observe that vaccination within 30 and 90 days before the second surge of Omicron variant provided different degrees of protection, consistent with waning of immunity even in individuals with multiple vaccine doses and history of infection[18]. As the length of follow-up in our study was relatively short, we were not able to analyze immunity duration over longer periods of time after the start of the second Omicron variant wave. This observation has implications for COVID-19 vaccination programmes: for example, under perfectly functioning logistics, it is possible that timing of vaccination campaigns, including for individuals who have been both previously infected and vaccinated,

limited; the majority (793/810) of these individuals had 3 doses before first Omicron

might be optimal if launched immediately after increase in incidence (e.g. linked to a new variant), rather than immediately after the end of a wave of infections.

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

In our analyses stratified by demographic characteristics, the protective effect of an additional vaccine dose was higher among patients who were 60 years of age or older than among younger individuals. As older individuals are more likely to suffer severe disease, including in settings similar to Shanghai[6], this finding suggests that vaccination of individuals in this age group, even after previous infection and vaccination, is beneficial. Similar to the findings of Ghorbani et al[19], we also found that the rate of reinfection in females was lower than in males; however, the protective effect of post-infection vaccine doses was similar in the two groups.

We also observed greater protection after an Ad5-nCoV vaccine dose in individuals who were fully vaccinated before their first SARS-CoV-2 infection compared to post-infection doses with other vaccine types. Note however that not all post-infection doses were of the same type of pre-infection vaccine doses. Another stratified analysis revealed that the protective effect of additional doses was different in individuals who had asymptomatic presentations of the first infection versus those who had symptomatic disease (aHR 0.80 [0.74, 0.87] and 1.01 [0.78, 1.29]). This could be related to different immune responses after infections with different severities. Indeed, reduced antibody response after the initial SARS-CoV-2 infection has been associated with incidence of reinfections. For example, in the study by Islamoglu and colleagues[20], it was observed that antibody responses against SARS-CoV-2 were protective against COVID-19 reinfection. Consistently, in the Republic of Korea, CD4⁺ T-cell responses tended to be greater in patients who had severe disease[21]. In agreement with these studies, that had different designs, our analysis suggests that individuals who had severe or critical COVID-19 had a lower risk of reinfection compared to those who were asymptomatic (see Table 1). Note that individuals who were asymptomatic and those with mild symptoms during the first infection had comparable rates of reinfection. However, individuals with unknown disease severity during the first infection had a higher reinfection rate compared to those with documented clinical severity. This is possibly due to the fact that asymptomatic individuals were more likely to experience home isolation or delayed transfer, leading to more frequent missing clinical severity data for this group.

Strengths of our study include: the well-defined timing of first infections and reinfections in Shanghai, linked to the two Omicron variant waves; detailed information on vaccination based on a citywide system; mass screening for SARS-CoV-2 infections during the first Omicron variant surge; free testing during the second Omicron wave. Further, to prevent immortal time bias, a common problem in epidemiological studies where treatment/exposure assignment is not aligned with the start of follow-up, we performed survival analysis that used a time varying exposure variable. The insights from our study are also likely generalizable to similar urban settings facing distinct waves of SARS-CoV-2 infections and that adopted the same vaccine types. However, our study also has limitations. Firstly, information on key variables, such as occupation, household registration, clinical severity during the first infection, were missing for a non-negligible fraction of the study population. Although in the primary analysis we performed adjustment for likely confounders, and in the secondary analysis we used propensity score matching, as in other observational studies, we cannot rule out the possibility of residual confounding, which in this context could be related to comorbidities that might affect both the decision to vaccinate after infection and risk of reinfection. Differences in healthcareseeking behavior could also bias case ascertainment between post-infection vaccinated and unvaccinated individuals[22], although, as we restricted the study population to individuals who had received at least one pre-infection dose, this potential bias might be more limited than in other vaccine studies.

Conclusions

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

Although SARS-CoV-2 vaccination, including booster doses, is recommended by the public health authorities in Shanghai to reduce the local disease burden caused by COVID-19, there is increasing unwillingness in the population to receive additional vaccine doses, and vaccine fatigue has been frequently reported. Our study provides evidence that there is additional value for individuals who have been vaccinated in receiving vaccine doses after infections. It also suggests that vaccination programmes need to be linked to efficient surveillance for new infections so that public health authorities can maximize impact of additional doses, including in this group of patients.

Materials and methods

4.1 Study setting and participants

During the first Omicron variant wave, the entire city of Shanghai entered a lockdown phase on April 1, 2022; and on June 1, 2022, the local government declared the end of the city-wide lockdown[6]. Residents (citizens, including immigrants from other provinces, and foreigners) in Shanghai, a provincial-level municipality in China with a population of more than 25 million people, underwent several rounds of SARS-CoV-2 RT-PCR testing between April 1 and May 31, 2022. This study included individuals diagnosed with their first SARS-CoV-2 infection between April 1 and May 31, 2022 in the Pudong District, Shanghai; both individuals who were diagnosed by mass screening and those with symptoms who were seen by healthcare professionals were included. Information on infection history as well as data on demographic variables (sex, age) were provided by Center for Disease Control and Prevention in Shanghai, China.

Additional information (e.g. on occupation, residence, clinical severity and symptoms of first infection) was available for patients with hospital records and those who were transferred to a hospital. The recorded clinical severity was categorized as asymptomatic, mild, moderate, severe, or critically ill[23, 24]. During the first Omicron variant wave in Shanghai, many Fangcang shelter hospitals were rapidly converted into facilities to treat COVID-19 patients and made important contributions in providing adequate healthcare to patients with mild to moderate symptoms, and preventing further viral transmission in the community[25]. The efficient referral and transfer mechanisms in the local communities meant that the majority of patients were admitted to Fangcang shelter hospitals one or two days after testing positive for SARS-CoV-2[26]. However, many patients were either admitted to hospital without complete clinical information or not transferred to other hospitals; for these study participants, information on clinical severity was often missing.

4.2 Study design and eligibility criteria

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

There was a second surge of Omicron variant cases from December 2022; and from January 2023, free nucleic acid testing services were no longer offered in Shanghai, and mandatory PCR testing on all personnel ceased. After this change, the cost of an individual test was 16 yuan (US\$2.33)[27]. For this reason, the outcome variable in our analysis was based on reinfection data collected prior to January 2023. Reinfection-related death was defined as death within 30 days of a SARS-CoV-2 reinfection[10]; individuals who died from reasons unrelated to COVID-19 between

the two Omicron variant waves were excluded. Individuals were also excluded if the date of first infection was missing. As the reasons why some individuals refused to receive vaccination varied and were often unknown[28], our analysis focused on individuals who had received at least one vaccine dose before the first SARS-CoV-2 infection.

4.3 Vaccination and reinfection data

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

The Shanghai Group Immunization System captures all vaccine administrations in the municipality and is updated daily. This system is linked to the National Immunization Program Information System, which also includes national identification-matched COVID-19 vaccinations received outside of Shanghai[8]. Vaccination status was categorized in accordance with national technical recommendations for COVID-19 vaccination[8]: unvaccinated, partially vaccinated, fully vaccinated and fully vaccinated with booster dose (here, also referred to as booster vaccination). Below, inactivated vaccines refer to Sinovac-CoronaVac, Sinopharm/BIBP COVID-19 vaccine, and Sinopharm/WIBP COVID-19 vaccine; Ad5-vectored vaccine refers to Cansino Ad5-nCoV-S COVID-19 vaccine; and recombinant protein vaccine refers to recombinant COVID-19 vaccine (CHO cell), Anhui Zhifei Longcom Biopharmaceutical Institute of Microbiology.

As in other epidemiological studies[19, 29], we defined reinfection as a positive SARS-CoV-2 RT-PCR or rapid antigen test at least 90 days after the first positive test. Phylogenetic analysis coupled with contact tracing data revealed community transmission of Omicron BA.5.2 sublineage in Shanghai[9]; the subvariant was estimated to have caused ~90% of infections during the second Omicron variant wave.

4.4 Statistical analysis

Continuous variables are summarized as medians and interquartile ranges (IQR), and categorical variables, as counts and proportions. Cumulative incidence of reinfections was calculated and expressed as the number of reinfected individuals per 100 participants. Cox proportional hazards models with a time varying exposure variable corresponding to post-infection vaccination were used to estimate adjusted hazard ratios (aHR). In this analysis, time to reinfection was the outcome, and postinfection vaccination, the exposure of interest; models were adjusted for sex, age, residence, occupation and clinical severity of the first SARS-CoV-2 infection. As, due to social distancing measures, the number of SARS-CoV-2 infections diagnosed

between May and November 2022 in Shanghai was low (N = 89 individuals), the start of the follow-up in the survival analysis was on December 1, and for each participant, the follow-up continued until January 3, 2023 or confirmed SARS-CoV-2 reinfection, whichever occurred earlier. We note that by using this approach, both the start of the follow-up and the eligibility (which required confirmed SARS-CoV-2 infection during the initial Omicron variant wave, and being at risk of infection when the second Omicron variant wave occurred in December) are temporally aligned. On the other hand, for some participants, the time of exposure (post-infection vaccination) occurred after time zero, which could potentially lead to immortal time bias[30]; for this reason, the exposure variable was as time-varying. We also assessed whether this effect was modified by demographic characteristics.

We conducted a secondary analysis to estimate the protection afforded by vaccination before the second Omicron variant wave (that is, only vaccine doses received before December 2022 were used in defining the exposure variable); this analysis was stratified by time intervals between post-infection vaccination and the second Omicron variant wave, and by post-infection vaccine type (for individuals who had the same vaccination status or the same number of doses before first infection). For this secondary analysis, propensity score matching was used to improve comparability between the exposed and unexposed groups; the propensity score was calculated using a logistic regression model with all available baseline characteristics, and a one-to-one matching was performed using the nearest neighbor matching method with a caliper width of 0.20[31]. We assessed the balance of covariates after matching using standardized mean differences (SMD), and considered a value of less than 0.1 to be indicative of adequate matching (**Table S2-4**). All statistical analyses were performed using R.4.1.1 software (Foundation for Statistical Computing, Vienna, Austria; https://www.r-project.org). We followed Strengthening the reporting of observational studies in epidemiology (STROBE) recommendations, and the STROBE checklist is provided in the Supplementary *Appendix* (**Table S7**)

Acknowledgments

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

426

427

We gratefully acknowledge all participants in this study. 425

Additional information

Funding 438

428

429

430

431

432

433

434

435

436

437

Funder	Grant reference number	Author	
Key Discipline Program of Pudong New Area Health System	PWZxk2022-25	Caoyi Xue	
Development and Application of Intelligent Epidemic Surveillance and Artificial Intelligence Analysis System	21002411400	Weibing Wang	
Shanghai Three-year Action Plan to Strengthen the Construction of Public Health System	GWVI-11.2-XD08	Caoyi Xue	

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions

- BZ, BG, WW and YY designed the study. CX, PD and BZ extracted the data and 440
- 441 constructed the database. BZ, JT and XL analyzed the data. BZ and WW drafted the
- manuscript—original draft. BG, XC, YY and WW conducted critical revisions of the 442
- manuscript—review and editing. All authors read and approved the final manuscript. 443
- 444 **Ethics**

- The study was approved by the Ethical Review Committee in the Shanghai Pudong 445
- 446 New Area Center for Disease Control and Prevention (approval number: PDCDCLL-
- 20220801-001). 447
- **Consent for publication** 448
- Not applicable. 449
- **Competing interests** 450

The authors declare that they have no known competing financial interest or personal relationship that could influence the work reported in this paper. **Additional files Supplementary files** Table S1. Descriptive overview of the study population. Table S2. Baseline demographic characteristics of unvaccinated and vaccinated groups after first infection stratified by dose received before first infection. Table S3. Baseline demographic characteristics of unvaccinated and vaccinated groups after first infection stratified by intervals before the policy change. Table S4. Baseline demographic characteristics of unvaccinated and vaccinated groups after first infection stratified by vaccination status prior infection. Table S5. Characteristics of vaccination distribution among study population. Table S6. Effect of vaccination after first infection against SARS-CoV-2 reinfection stratified by sequence of vaccination dose and vaccination status before first infection. Table S7. STROBE Statement. Figure S1. Vaccination status coverage in the study population. Figure S2. Effect of vaccine dose on SARS-CoV-2 reinfection stratified by preinfection vaccination and not adjusted for the severity of the first infection. **Data availability** The individual-level data used in this study are sensitive and cannot be publicly shared. Requests for data should be made to the Shanghai Pudong New Area Center

for Disease Control and Prevention.

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

References

- 476 1. Pan Y, Wang L, Feng Z, Xu H, Li F, Shen Y, Zhang D, Liu WJ, Gao GF, Wang Q:
- 477 Characterisation of SARS-CoV-2 variants in Beijing during 2022: an epidemiological
- 478 and phylogenetic analysis. *Lancet* 2023, **401**(10377):664-672.
- 2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R et al.
- 480 A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med
- 481 2020, **382**(8):727-733.
- 482 3. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, Anyaneji UJ,
- 483 Bester PA, Boni MF, Chand M et al. Rapid epidemic expansion of the SARS-CoV-2
- 484 **Omicron variant in southern Africa**. *Nature* 2022, **603**(7902):679-686.
- 485 4. Zhou Y, Zhi H, Teng Y: The outbreak of SARS-CoV-2 Omicron lineages, immune
- 486 escape, and vaccine effectivity. J Med Virol 2023, 95(1):e28138.
- 487 5. Li J, Lai S, Gao GF, Shi W: The emergence, genomic diversity and global spread of
- 488 **SARS-CoV-2**. *Nature* 2021, **600**(7889):408-418.
- 489 6. Chen X, Yan X, Sun K, Zheng N, Sun R, Zhou J, Deng X, Zhuang T, Cai J, Zhang J
- 490 et al. Estimation of disease burden and clinical severity of COVID-19 caused by
- 491 Omicron BA.2 in Shanghai, February-June 2022. Emerg Microbes Infect 2022,
- **492 11**(1):2800-2807.
- 493 7. Zheng L, Liu S, Lu F: Impact of National Omicron Outbreak at the end of 2022 on the
- future outlook of COVID-19 in China. *Emerg Microbes Infect* 2023, **12**(1):2191738.
- 495 8. Huang Z, Xu S, Liu J, Wu L, Qiu J, Wang N, Ren J, Li Z, Guo X, Tao F et al.
- 496 Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai:
- retrospective cohort study. *Nat Commun* 2023, **14**(1):2009.
- 498 9. Huang Z, Xu S, Liu J, Wu L, Qiu J, Wang N, Ren J, Li Z, Guo X, Tao F et al.
- 499 Effectiveness of inactivated and Ad5-nCoV COVID-19 vaccines against SARS-CoV-2
- Omicron BA. 2 variant infection, severe illness, and death. *BMC Med* 2022, **20**(1):400.
- 501 10. Nielsen KF, Moustsen-Helms IR, Schelde AB, Gram MA, Emborg HD, Nielsen J,
- Hansen CH, Andersen MA, Meaidi M, Wohlfahrt J et al. Vaccine effectiveness against
- 503 SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A
- 504 **Danish nationwide study**. *PLoS Med* 2022, **19**(11):e1004037.
- 505 11. Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, Selemon A, Whelan M, Premji Z,
- 506 Issa H et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid
- 507 immunity against the omicron variant and severe disease: a systematic review and
- 508 meta-regression. *Lancet Infect Dis* 2023, **23**(5):556-567.
- 509 12. Gazit S, Saciuk Y, Perez G, Peretz A, Ben-Tov A, Stuart EA, Patalon T: Hybrid
- immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2
- 511 infection and single dose of the BNT162b2 vaccine in children and adolescents: a
- target trial emulation. *Lancet Microbe* 2023, **4**(7):e495-e505.
- 513 13. Altarawneh HN, Chemaitelly H, Ayoub HH, Hasan MR, Coyle P, Yassine HM, Al-

perpetuity.

It is made available under a CC-BY 4.0 International license .

514 Khatib HA, Smatti MK, Al-Kanaani Z, Al-Kuwari E et al. Protective Effect of Previous 515 SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. N Engl J Med 516 2022, 387(17):1620-1622. 517 14. Hammerman A, Sergienko R, Friger M, Beckenstein T, Peretz A, Netzer D, Yaron S, 518 Arbel R: Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19. N 519 Engl J Med 2022, 386(13):1221-1229. 520 Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Yassine HM, Benslimane FM, Al Khatib 15. 521 HA, Tang P, Hasan MR, Coyle P, Al Kanaani Z et al. Association of Prior SARS-CoV-522 2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar. 523 Jama 2021, 326(19):1930-1939. 524 16. Lewis N, Chambers LC, Chu HT, Fortnam T, De Vito R, Gargano LM, Chan PA, McDonald J, Hogan JW: Effectiveness Associated With Vaccination After COVID-19 525 526 Recovery in Preventing Reinfection. JAMA Netw Open 2022, 5(7):e2223917. 527 17. Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K: Reduced Risk of 528 Reinfection with SARS-CoV-2 After COVID-19 Vaccination - Kentucky, May-June 529 **2021**. MMWR Morb Mortal Wkly Rep 2021, **70**(32):1081-1083. 530 18. Ferdinands JM, Rao S, Dixon BE, Mitchell PK, DeSilva MB, Irving SA, Lewis N, 531 Natarajan K, Stenehjem E, Grannis SJ et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test 532 533 negative, case-control study. Bmj 2022, 379:e072141. 534 19. Sotoodeh Ghorbani S, Taherpour N, Bayat S, Ghajari H, Mohseni P, Hashemi Nazari 535 SS: Epidemiologic characteristics of cases with reinfection, recurrence, and hospital 536 readmission due to COVID-19: A systematic review and meta-analysis. J Med Virol 537 2022, 94(1):44-53. 538 20. Islamoglu MS, Cengiz M, Uvsal BB, Ikitimur H, Ozdemir Z, Karamehmetoglu A. 539 Akbulut AE, Bakdur AN, Ozdemir A, Kayıkcıoglu H et al. Relationship between 540 Antibody Levels and SARS-Cov-2 Reinfection. Ann Clin Lab Sci 2021, 51(6):750-755. 541 21. Kang CK, Kim M, Lee S, Kim G, Choe PG, Park WB, Kim NJ, Lee CH, Kim IS, Jung 542 K et al. Longitudinal Analysis of Human Memory T-Cell Response According to the 543 Severity of Illness up to 8 Months After Severe Acute Respiratory Syndrome 544 Coronavirus 2 Infection. J Infect Dis 2021, 224(1):39-48. 545 22. Yung CF, Pang D, Kam KQ, Lye DC, Ong B, Chong CY, Tan KB: BNT162b2 vaccine 546 protection against omicron and effect of previous infection variant and vaccination 547 sequence among children and adolescents in Singapore: a population-based cohort 548 study. Lancet Child Adolesc Health 2023. 549 Chen Z, Deng X, Fang L, Sun K, Wu Y, Che T, Zou J, Cai J, Liu H, Wang Y et al. 23. 550 Epidemiological characteristics and transmission dynamics of the outbreak caused by

the SARS-CoV-2 Omicron variant in Shanghai, China: A descriptive study. Lancet

Reg Health West Pac 2022, 29:100592.

551

perpetuity.

It is made available under a CC-BY 4.0 International license .

553 24. Ge Y, Martinez L, Sun S, Chen Z, Zhang F, Li F, Sun W, Chen E, Pan J, Li C et al. 554 COVID-19 Transmission Dynamics Among Close Contacts of Index Patients With 555 COVID-19: A Population-Based Cohort Study in Zhejiang Province, China. JAMA 556 Intern Med 2021, 181(10):1343-1350. 25. 557 Zhang X, Zhang W, Chen S: Shanghai's life-saving efforts against the current 558 omicron wave of the COVID-19 pandemic. Lancet 2022, 399(10340):2011-2012. 559 Ye L, Li WF, Shao J, Xu Z, Ju J, Xu H: Fighting Omicron epidemic in China: Real-26. 560 world big data from Fangcang shelter hospital during the outbreak in Shanghai 2022. 561 J Infect 2022, 85(4):436-480. 562 27. No more free PCR tests in Shanghai from Sunday 563 [https://www.shine.cn/covid19/2301064857/] 564 Wu J, Li Q, Silver Tarimo C, Wang M, Gu J, Wei W, Ma M, Zhao L, Mu Z, Miao Y: 28. 565 COVID-19 Vaccine Hesitancy Among Chinese Population: A Large-Scale National 566 Study. Front Immunol 2021, 12:781161. 567 29. Investigative criteria for suspected cases of SARS-CoV-2 reinfection (ICR) 568 [https://stacks.cdc.gov/view/cdc/96072] 569 30. Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I: Specifying a target trial 570 prevents immortal time bias and other self-inflicted injuries in observational analyses. 571 J Clin Epidemiol 2016, **79**:70-75. 572 31. Ueno M, Komeda K, Kosaka H, Nakai T, Nomi T, Iida H, Tanaka S, Ikoma H, 573 Matsuda K, Hirokawa F et al. Prognostic impact of neoadjuvant chemotherapy in 574 patients with synchronous colorectal liver metastasis: A propensity score matching 575 comparative study. Int J Surg 2021, 94:106106. 576

Table 1. Characteristics of the study population and reinfection rate by post-infection vaccination status. Here, reinfection rate refers to the percentage of the relevant study subpopulation with evidence of reinfection between December 1, 2022 and January 3, 2023. Note that for the variables on region, occupation, and clinical severity, data are missing for large fractions of the study population.

		All		No post-infection vaccination		Post-infection vaccination	
	Characteristics	N (%)	Reinfection rate, % (95% CI).	N (%)	Reinfection rate, % (95% CI).	N (%)	Reinfection rate, % (95% CI).
Overall		199,312	24.4 (24.2, 24.6)	183,165	24.7 (24.5, 24.9)	16,147	21.5 (20.8, 22.2)
Sex	Male	112,672 (56.5)	26.1 (25.8, 26.4)	104,002 (56.8)	26.4 (26.1, 26.7)	8,670 (53.7)	22.3 (21.3, 23.3)
	Female	85,804 (43.1)	22.4 (22.1, 22.7)	78,403 (42.8)	22.9 (22.6, 23.2)	7,401 (45.8)	17.4 (16.4, 18.3)
Age, years	0-6	1,736 (0.9)	7.0 (5.8, 8.3)	1,569 (0.9)	6.6 (5.4, 8.0)	167 (1.0)	10.2 (6.2, 15.9)
	7-19	10,762 (5.4)	13.0 (12.3, 13.7)	10,347 (5.6)	12.9 (12.3, 13.6)	415 (2.6)	14.7 (11.4, 18.8)
	20-39	75,955 (38.1)	22.4 (22.1, 22.8)	71,005 (38.8)	22.7 (22.3, 23.0)	4,950 (30.7)	19.1 (17.9, 20.3)
	40-59	74,680 (37.5)	29.4 (29.0, 29.8)	70,569 (38.5)	29.6 (29.2, 30.0)	4,111 (25.5)	25.8 (24.2, 27.4)
	60+	35,903 (18.0)	22.6 (22.1, 23.1)	29,446 (16.1)	23.7 (23.1, 24.2)	6,457 (40.0)	17.6 (16.6, 18.6)
Regions	Shanghai	44,259 (22.2)	18.9 (18.5, 19.3)	41,250 (22.5)	19.4 (19.0, 19.9)	3,009 (18.6)	11.9 (10.7, 13.1)
	Other provinces	44,959 (22.6)	20.9 (20.5, 21.3)	43,045 (23.5)	21.0 (20.6, 21.5)	1,914 (11.9)	18.2 (16.4, 20.2)
Occupations	Preschoolers and students	12,232 (6.1)	12.1 (11.5, 12.7)	11,677 (6.4)	12.0 (11.4, 12.6)	555 (3.4)	13.2 (10.4, 16.4)
	Employed	29,537 (14.8)	20.8 (20.2, 21.3)	28,343 (15.5)	20.8 (20.3, 21.4)	1,194 (7.4)	18.8 (16.4, 21.3)
	Retired	37,482 (18.8)	22.5 (22.0, 23.0)	30,955 (16.9)	23.5 (23.0, 24.1)	6,527 (40.4)	17.5 (16.5, 18.5)
	Working age not in labor [†]	5,606 (2.8)	21.0 (19.8, 22.2)	5,311 (2.9)	21.5 (20.3, 22.8)	295 (1.8)	11.5 (8.1, 15.9)
Clinical	Asymptomatic	81,584 (40.9)	19.9 (19.6, 20.2)	77,057 (42.1)	20.3 (19.9, 20.6)	4,527 (28.0)	14.1 (13.1, 15.3)
severity*	Mild/moderate	7,602 (3.8)	19.9 (18.9, 21.0)	7,216 (3.9)	20.1 (19.1, 21.2)	386 (2.4)	16.6 (12.9, 21.0)
	Severe or critical	32 (0.0)	15.6 (5.9, 34.3)	22 (0.0)	13.6 (3.8, 36.4)	10 (0.1)	20.0 (4.0, 64.1)

CI: confidence interval; † people of working age (≥18 years) unemployed or not in the labor force (disabled); *Clinical severity of first infection.

perpetuity.

It is made available under a CC-BY 4.0 International license .




Figure 1. Flow chart describing the selection of participants for the analysis. The number of individuals in this figure is not the same as some of the numbers in **Table 1** because of missing data in key variables.

582

583

584

perpetuity.

It is made available under a CC-BY 4.0 International license .




Figure 2. Vaccination coverage and cumulative incidence of SARS-CoV-2 reinfection in the study population. Panel A presents the percentages of the study population vaccinated over time. The cumulative incidence of SARS-CoV-2 reinfections is presented by the number of vaccination doses before (panels) and after (lines) first infection (panels B-C). Shaded regions: 95% CIs. 1V-I, 2V-I represented 1, 2 and 3 vaccine doses before infection, respectively; 1V-I-V, 2V-I-V corresponds to 1 and 2 doses before infection, then post-infection vaccination, respectively. As mentioned in the *Results* section, 142 and 144 study participants who received one and two pre-infection vaccine doses received two post-infection vaccine doses. We do not show the corresponding plot for those individuals who received 3 pre-infection doses as their post-infection dose was after the start of the follow-up, in December.




Figure 3. Effect of vaccine dose on SARS-CoV-2 reinfection stratified by preinfection vaccination. Error bars (95% CIs) and circles represent aHR for SARS-CoV-2 reinfection estimated using Cox proportional hazards models. 1V-I-V, 2V-I-V, 3V-I-V corresponds to 1, 2 and 3 vaccine doses before infection, then vaccination, respectively; they were compared to 1V-I, 2V-I, 3V-I, respectively. V-I-V, Partial V-I-V, Full V-I-V and Booster V-I-V represent any pre-infection vaccination, partial vaccination, full vaccination and booster vaccination before infection, followed by post-infection vaccination, respectively.




Figure 4. Vaccine-related protection against SARS-CoV-2 reinfection stratified by demographic characteristic. The vertical dotted line at 1.0 indicates no effect on protection.